Can sensitivity to cytotoxic chemotherapy be predicted by biomarkers?

被引：6

作者：

Felip, E. ^{[1
]}

Martinez, P. ^{[1
]}

机构：

[1] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2012年 / 23卷

关键词：

biomarkers; chemotherapy; NSCLC; predictive; prognostic; CELL LUNG-CANCER; BIO POOLED ANALYSIS; PHASE-III TRIAL; ADJUVANT CHEMOTHERAPY; 1ST-LINE TAXANE/CARBOPLATIN; MESSENGER-RNA; UP-REGULATION; EXPRESSION; CISPLATIN; CETUXIMAB;

D O I：

10.1093/annonc/mds309

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Non-small-cell lung cancer is the leading cause of cancer-related death worldwide with poor outcomes, even when a curative treatment approach is feasible. Chemotherapy remains a useful option for the majority of patients with advanced or relapsed disease as well as having a substantial role in the adjuvant setting. Identifying predictive biomarkers would enable us to better select those patients more likely to benefit from chemotherapy while avoiding toxic effects in those patients not deriving benefit from chemotherapy. Although the use of biomarkers to select chemotherapy is not the standard approach, several potential biomarkers have been identified and a few prospective trials are ongoing. We review here the most-studied biomarkers for chemotherapy.

引用

页码：189 / 192

页数：4

共 34 条

[1] Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy [J].

Azuma, Koichi ;

Komohara, Yoshihiro ;

Sasada, Tetsuro ;

Terazaki, Yasuhiro ;

Ikeda, Jiro ;

Hoshino, Tomoaki ;

Itoh, Kyogo ;

Yamada, Akira ;

Aizawa, Hisamichi .

CANCER SCIENCE, 2007, 98 (09) :1336-1343

[2] RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer [J].

Bepler, Gerold ;

Kusmartseva, Irina ;

Sharma, Swati ;

Gautam, Ashish ;

Cantor, Alan ;

Sharma, Anupama ;

Simon, George .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4731-4737

[3] Prognostic and predictive role of alterations of the P53-bax-bcl2 pathway of apoptosis in the IALT (International Adjuvant Lung Cancer Trial) [J].

Brambilla, E ;

Dunant, A ;

Filipits, M ;

Lantuejoul, S ;

Tarayre, M ;

David-Boudet, L ;

Pirker, R ;

Soria, J ;

Pignon, J ;

Le Chevalier, T .

LUNG CANCER, 2005, 49 :S10-S11

[4]

BRAMBILLA E, 2010, CHICAGO MULTIDISCIPL

[5] Impact of KRAS mutations on adjuvant carboplatin/paclitaxel in surgically resected stage IB NSCLC: CALGB 9633. [J].

Capelletti, M. ;

Wang, X. F. ;

Gu, L. ;

Graziano, S. L. ;

Kratzke, R. A. ;

Strauss, G. M. ;

Maddaus, M. ;

Green, M. R. ;

Vokes, E. E. ;

Janne, P. A. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[6] ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine [J].

Ceppi, P. ;

Volante, M. ;

Novello, S. ;

Rapa, I. ;

Danenberg, K. D. ;

Danenberg, P. V. ;

Cambieri, A. ;

Selvaggi, G. ;

Saviozzi, S. ;

Calogero, R. ;

Papotti, M. ;

Scagliotti, G. V. .

ANNALS OF ONCOLOGY, 2006, 17 (12) :1818-1825

[7] Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase [J].

Ceppi, Paolo ;

Volante, Marco ;

Saviozzi, Silvia ;

Rapa, Ida ;

Novello, Silvia ;

Cambieri, Alberto ;

Lo Iacono, Marco ;

Cappia, Susanna ;

Papotti, Mauro ;

Scagliotti, Giorgio V. .

CANCER, 2006, 107 (07) :1589-1596

[8]

Cobo M, 2008, J CLIN ONCOL, V26, P15

[9] Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression:: A phase III trial in non-small-cell lung cancer [J].

Cobo, Manuel ;

Isla, Dolores ;

Massuti, Bartomeu ;

Montes, Ana ;

Miguel Sanchez, Jose ;

Provencio, Mariano ;

Vinolas, Nuria ;

Paz-Ares, Luis ;

Lopez-Vivanco, Guillermo ;

Angel Munoz, Miguel ;

Felip, Enriqueta ;

Alberola, Vicente ;

Camps, Carlos ;

Domine, Manuel ;

Sanchez, Jose Javier ;

Sanchez-Ronco, Maria ;

Danenberg, Kathleen ;

Taron, Miquel ;

Gandara, David ;

Rosell, Rafael .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (19) :2747-2754

[10] Human MutS alpha recognizes damaged DNA base pairs containing O-6-methylguanine, O-4-methylthymine, or the cisplatin-d(GpG) adduct [J].

Duckett, DR ;

Drummond, JT ;

Murchie, AIH ;

Reardon, JT ;

Sancar, A ;

Lilley, DM ;

Modrich, P .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (13) :6443-6447

← 1 2 3 4 →